<DOC>
	<DOCNO>NCT00004142</DOCNO>
	<brief_summary>RATIONALE : Radiofrequency ablation may able shrink destroy cancer cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemotherapy deliver directly blood vessel liver may prevent new tumor grow . Combining therapy may effective treatment colorectal cancer spread liver . PURPOSE : Phase II trial study effectiveness radiofrequency ablation follow chemotherapy deliver directly blood vessel liver treat patient colorectal cancer spread liver .</brief_summary>
	<brief_title>Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy Treating Patients With Colorectal Cancer That Has Spread Liver</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy radiofrequency tissue ablation follow hepatic arterial chemotherapy floxuridine fluorouracil patient colorectal cancer metastatic liver . OUTLINE : Patients undergo open laparotomy identify target tumor liver use intraoperative ultrasound follow radiofrequency tissue ablation 20 minute tumor placement hepatic arterial catheter . Within 35 day postoperatively , patient receive hepatic arterial chemotherapy consist floxuridine day 1-7 fluorouracil 1 hour day 15 , 22 , 29 . Treatment repeat every 5 week 6 course . Patients follow 1 month , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer metastatic liver No preoperative intraoperative evidence extrahepatic metastasis include clinical , radiographic , gross microscopic evidence Tumors must 4 cm diameter No 6 total tumor May fail prior systemic chemotherapy Failure 1 prior intraarterial regimen exclude floxuridine , fluorouracil , another fluoropyrimidine allow liver enzymes recovered No evidence cirrhosis No gross ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 16 week Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No active duodenal gastric ulcer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 68 week since nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy liver Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>